Pharmafile Logo
T40 2022 Cover
Diversity, Equity and Inclusion
Communiqué 53 Cover Image
- PMLiVE

priority access

- PMLiVE

Rare cancer specialists Sierra Oncology acquired by GSK for £1.5bn

Unification will help to uphold and progress promising Momelotinib treatment which targets myelofibrosis

- PMLiVE

GSK and CureVac sign deal with Germany for mRNA COVID-19 vaccines

The agreement is part of a Pandemic Preparedness Contract and means millions of vaccines can be produced at short notice during future public health emergencies

- PMLiVE

Novartis restructures organisation to support growth and innovation

The new operational structure will involve integrating pharmaceuticals and oncology business units into an Innovative Medicines business

- PMLiVE

AstraZeneca to present new oncology data at AACR

The American Association for Cancer Research Annual Meeting takes place in New Orleans from 8-13 April 2022

- PMLiVE

CHMP recommends marketing authorisation for AZ’s Evusheld in the EU

The treatment can be used to prevent people contracting COVID-19 and can be given to adults and children aged 12 years and older

- PMLiVE

Novartis’ Kesimpta trial evaluates treatment of COVID-19 in MS patients

There are an estimated 130,000 people with MS in the UK

- PMLiVE

FDA approves Novartis’ Pluvicto for prostate cancer

The treatment is the first FDA approved targeted radioligand therapy for mCRPC patients

- PMLiVE

AstraZeneca’s Alexion agrees on $775m settlement with Chugai for Ultomiris

The two companies will withdraw patent infringement proceedings filed with the US and Japan

- PMLiVE

Merck KGaA to make $3m payout to patients after drug formulation complaints

La Cour de Cassation has ordered the company to make the payment to more than 3,000 patients to settle the reformulation dispute

- PMLiVE

MHRA grants approval for AstraZeneca’s Evusheld in the UK

It is the first antibody combination treatment authorised for use before exposure to COVID-19 infection in order to prevent disease licensed in the UK

- PMLiVE

AstraZeneca and MSD’s breast cancer drug Lynparza receives FDA approval

An estimated 2.3 million patients were diagnosed with breast cancer in 2020

- PMLiVE

Ovarian Cancer Commitment announced to improve patient care

The coalition was announced by ENGAGe, ESGO and AstraZeneca in a call to improve ovarian cancer care

Subscribe to our email news alerts

Latest jobs from #PharmaRole

Latest content

Latest intelligence

Quick links